Acrolein Quickview (CASRN 107-02-8)

Status of Data for Acrolein

File First On-Line: 09/07/1988; Last Significant Revision: 06/03/2003

Category (section)	Status	Last Revised
Oral RfD Assessment	On-line	06/03/2003
Inhalation RfC Assessment	On-line	06/03/2003
Carcinogenicity Assessment	On-line	06/03/2003

Synonyms

107-02-8 Acraldehyde Acrolein Acrylaldehyde 2-Propenal

Allyl aldehyde Ethylene aldehyde Propenal Prop-2-en-l-al

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect	Point of Departure*	UF	MF	RfD
Decreased survival	NOAEL : 0.05 mg/kg-day	100	1	5 x10-4 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Oral RfD)
  • Chronic gavage rat study, Parent et. al., 1992a
• Confidence in the Oral RfD
  • Study -- Medium
  • Database -- High
  • RfD -- Medium/High

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect	Point of Departure*	UF	MF	RfC
Nasal lesions	LOAEL (HEC): 0.02 mg/m3	1000	1	2x10-5 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Inhalation RfC)
  • Subchronic rat inhalation study, Feron et. al., 1978
• Confidence in the Inhalation RfC
  • Study -- Medium
  • Database -- Low/Medium
  • RfC -- Medium

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • Data are inadequate for an assessment of human carcinogenic potential
• Weight-of-Evidence Narrative:
  • Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the potential carcinogenicity of acrolein cannot be determined because the existing data are inadequate for an assessment of human carcinogenic potential for either the oral or inhalation route of exposure. There are no adequate human studies of the carcinogenic potential of acrolein. Collectively, experimental studies provide inadequate evidence that acrolein causes cancer in laboratory animals.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

• Not Assessed under the IRIS Program.

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

• Not Assessed under the IRIS Program.